Navigation Links
Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
Date:1/28/2008

The VenaFlux(TM) Platform Accurately Mimics a Human Capillary

DUBLIN, Ireland, Jan. 28 /PRNewswire/ -- Cellix Ltd., an international provider of microfluidic systems in the emerging field of nano-lifesciences, announced today its worldwide launch of its VenaFlux(TM) Platform. The VenaFlux(TM), the first semi-automated, high throughput microfluidic cell- based assay system, measures cell adhesion to antibody-coated or endothelial- cell cultured microchannels, producing IC50 curves under shear stress conditions mimicking physiological flow. The system thereby offers scientists an important and unique tool for drug discovery. The VenaFlux(TM) is simple to use, reduces costly layers of animal model studies, and delivers specific, accurate, and reproducible results.

Using the VenaFlux(TM), scientists can rapidly obtain quantitative analyses and results for potential drug candidates in therapeutic areas including cardiovascular, respiratory, immunologic, autoimmune and oncologic disease states. Relatively rapid analyses reduces drug development costs by accelerating false lead elimination and increasing productivity in pharmaceutical and biotechnology research and development laboratories.

"Understanding how cells behave in human capillaries is an expanding area in global research and development for discovering new patient therapies," said Vivienne Williams, CEO of Cellix Ltd. "Our VenaFlux(TM) accurately replicates cell behavior in human capillaries, an in vitro modeling system that has previously been difficult to achieve.

Cellix's technology provides researchers with a single platform for executing dynamic studies to analyze the effects of drugs on cell adhesion, proliferation and transmigration under well-defined shear stress protocols that replicate physiological conditions. "To date, pharmaceutical companies including AstraZeneca and Amgen, as well as research institutions such as the US National Institutes of Health have adopted Cellix's technology to characterize drug effects," commented Ms. Williams.

About the VenaFlux Platform

The VenaFlux(TM) Platform consists of Cellix's patented Mirus(TM) Nanopump with VenaFluxAssay(TM) software, Vena8(TM) Biochips and DucoCell(TM) analysis software; Carl Zeiss Axiovert(TM) 40 CFL microscope, motorized stage with Z- focus, microscope cage incubator, automated dispenser arm, digital camera for image acquisition and PC. The VenaFlux(TM) Platform can run 8 microcapillaries in 15 minutes, thereby achieving 32 assays in one hour or approximately 1,000 assays per week. The VenaFlux(TM) Platform provides an important new in vitro alternative to expensive animal models while simultaneously cutting down costs on reagents and manpower.

About Cellix Ltd.

Cellix Ltd. is a privately held instrumentation and cell-based assay company developing technologies that accurately mimic cellular behavior in vivo for cell-based screening in drug discovery. The Company is headquartered in Dublin, Ireland, and maintains offices in New York City. For further information visit http://www.cellixltd.com


'/>"/>
SOURCE Cellix Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers
2. PennWell Launches Bio-Optics World Magazine and Web Site
3. DRI Capital Launches Structured Finance Fund
4. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
5. LineaGen Inc. Launches With Close of $5.8 Million Series A Funding Round
6. SleepQuest Launches Updated Web Site
7. Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15%
8. DeviceSpace.com Launches Marketing Campaign for US Medical Device Industry
9. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
10. Vical Launches Redesigned Website
11. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... 2017 , ... Franz Inc ., an early innovator ... market leader for Semantic Graph Database technology, today announced Allegro ... effective system for developing and deploying applications to solve the challenges developers face ...
(Date:4/25/2017)... ... April 25, 2017 , ... Dr. Robert G. Schwartz, ... proudly announced today that acclaimed physiatrist Matthew Terzella, MD, has joined the practice ... , Dr. Terzella completed his residency in Physical Medicine and Rehabilitation at UMDNJ-Robert ...
(Date:4/24/2017)... ... April 24, 2017 , ... It ... a cellular milieu; however, the broad application of this cellular target engagement concept ... sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods for particular applications, ...
(Date:4/21/2017)... TX (PRWEB) , ... April 21, 2017 , ... Having ... than a year, Formaspace is pleased to introduce it to top lab design architects ... Formaspace CEO Jeff Turk and VP of Industrial Design and Engineering Greg Casey will ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):